Non-Small Cell Lung Cancer

Latest News

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
Survival Outcomes in Advanced NSCLC Improved With Use of Cemiplimab

September 10th 2025

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

AI gen NSCLC lungs | Image credit: PRASANNAPIX - stock.adobe.com
Cemiplimab Shows 5-Year Survival Benefit in Advanced NSCLC With High PD-L1 Expression

September 8th 2025

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
Cancer-Specific Outcomes Improved With Adherence to Quality Metrics

September 3rd 2025

Advances in Oncology: When Innovation and Challenge Intersect
Advances in Oncology: When Innovation and Challenge Intersect

August 21st 2025

For Better Cancer Outcomes, It’s All About Access
For Better Cancer Outcomes, It’s All About Access

August 21st 2025

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo
Continuing Medical Education
View All
September 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

5 experts in this video
May 19th 2025

Navigating ALK Inhibitor Toxicities

Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how ALK inhibitors compare in terms of tolerability and best practices for managing associated toxicities.
5 experts in this video
May 19th 2025

Key Differences Among ALK Inhibitors

Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
5 experts in this video
May 12th 2025

Applying Trial Data to Real-World Practice in ALK+ NSCLC

Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
5 experts in this video
May 12th 2025

Choosing Wisely: Insights from an MAIC and eXalt3

Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).
5 experts in this video
May 5th 2025

Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
5 experts in this video
May 5th 2025

The Evolution of ALK+ NSCLC Care

Ryan Haumschild, PharmD, MS, MBA, CPEL Elizabeth Castronovo, NP Martin Dietrich, MD, PhD Mary Grizzard, MSN, FNP Christine M. Lovly, MD, PhD, FASCO
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Krazati packaging | Image credit: Mirati Therapeutics
March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC

Mary Caffrey
Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.
Ioana Bonta, MD
February 20th 2025

NSCLC Advancements Offer Hope, but Disparities Persist

Kyle Munz Ioana Bonta, MD
Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Edgardo S. Santos, MD, FACP, FASCO
January 11th 2025

How Early Detection, Precision Medicine Can Impact Lung Cancer Outcomes

Skylar Jeremias
Edgardo S. Santos, MD, FACP, FASCO, emphasized the need to eliminate the stigma around smoking in lung cancer, highlighted the importance of early detection and discussed how advances in precision medicine, genomic studies, and targeted therapies have improved patient outcomes and reduced health care costs.
Edgardo S. Santos, MD, FACP, FASCO
January 5th 2025

Combining Liquid and Tissue Biopsies for Better Lung Cancer Care

Skylar Jeremias
Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient concerns about technology understanding and insurance coverage, as well as the reliance on traditional tissue biopsies, emphasizing the benefits of combining liquid and tissue biopsies to improve treatment outcomes and clinical trial eligibility.
Edgardo S. Santos, MD, FACP, FASCO
January 1st 2025

Revolutionizing Lung Cancer Care: The Impact of Liquid Biopsies

Skylar Jeremias
Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, less invasive diagnostics, with key applications in early detection, predictive biomarker identification, treatment response monitoring, resistance mechanism assessment, and minimal residual disease detection.
Ryan Nguyen, DO
January 1st 2025

AI in Oncology: Opportunities and Challenges for NSCLC

Skylar Jeremias
Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.
WCLC Highlights Thumbnail
December 27th 2024

ICYMI: Highlights From WCLC 2024

Maggie L. Shaw
The 2024 World Conference on Lung Cancer (WCLC) took place in San Diego, California, from September 7 to 10, 2024.
Ryan Nguyen, MD
December 23rd 2024

Precision Oncology in NSCLC: Overcoming Patient Selection Barriers

Skylar Jeremias
Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.
NSCLC Thumbnail
December 20th 2024

Top 5 NSCLC Content for 2024

Maggie L. Shaw
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.
FDA approval. | Image Credit: Pawel - stock.adobe.com
December 19th 2024

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC

Cameron Santoro
The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.
Syringe and vials | Image credit: Aliaksandr Marko – stock.adobe.com
December 17th 2024

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Hayden E. Klein
Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.
Lungs | image credit: istock photo
December 13th 2024

Updated Data Show Zongertinib Yields Responses in 71% With Previously Treated HER2-Mutated NSCLC

Mary Caffrey
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
December 13th 2024

Next-Gen Strategies for Resistance in EGFR-Mutated Lung Cancer

Maggie L. Shaw
To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome treatment resistance in non–small cell lung cancer.
Bhuvana Sagar, MD
December 9th 2024

What Do Liquid Biopsies Add to Value-Based Cancer Care?

Hayden E. Klein
Payers want to make sure patients are getting biopsies done so they can get on the right therapies, said Bhuvana Sagar, MD, Oncology Consultants.
FDA approval with stamp | Image Credit: Surendra - stock.adobe.com
December 5th 2024

Zenocutuzumab Approved for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Laura Joszt, MA
The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.
Divya Gupta, MD
December 4th 2024

Optimizing Outcomes in NSCLC With Precision Medicine and Teamwork

Skylar Jeremias
Divya Gupta, MD, assistant professor at the Northwestern University Feinberg School of Medicine, emphasized the transformative role of biomarker-driven therapies in advancing non–small cell lung cancer (NSCLC) treatment and highlighted the critical importance of multidisciplinary collaboration.
Immunotherapy | Image Credit: © kentoh-stock.adobe.com
December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw
Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.
Divya Gupta, MD
November 28th 2024

Revolutionizing NSCLC Care With Circulating Tumor DNA and MRD Assays

Skylar Jeremias
Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for personalized treatment in non–small cell lung cancer (NSCLC), while emphasizing the unmet need for effective second-line therapies for patients without driver mutations.
Lungcancertreatment | Image Credit: © Vitalii Vodolazskyi-stock.adobe.com
November 27th 2024

Durvalumab Underutilization Highlights Gaps in NSCLC Treatment Strategies

Maggie L. Shaw
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients who have unresectable stage III non–small cell lung cancer (NSCLC).
Martin Dietrich, MD, PhD
November 21st 2024

Research Priorities Evolve With Amivantamab's Broader NSCLC Indications

Maggie L. Shaw
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).
FDA | Image Credit: © Artur-stock.adobe.com
November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

Ashling Wahner
The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).
Lung cancer | Image Credit: © Crystal light - stock.adobe.com
November 15th 2024

Tailored Management Needed for Male Patients With NSCLC After Surgery

Maggie L. Shaw
Lung cancer is the top cause of cancer-related death worldwide.
Ticiana Leal, MD
November 13th 2024

Perioperative Strategies in NSCLC: Future Directions and Challenges

Rose McNulty Maggie L. Shaw
In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.
<123456>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo